ANDA 77077, held by Ph Health. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 77077 (Gildess Fe 1/20, Gildess 1/20), held by Ph Health, was first approved by FDA on May 20, 2005, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 20, 2005 | Original application | Approved | None posted |
| Gildess Fe 1/200.02MG;1MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Gildess 1/200.02MG;1MG · tablet;oral-21 | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Sep 29, 2016 | Supplement 11Manufacturing | Approved | None posted |
| Nov 28, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 27, 2009 | Supplement 2Labeling | Approved | None posted |
| May 20, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters